2020
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion On Drug Discovery 2020, 16: 125-134. PMID: 33086894, DOI: 10.1080/17460441.2020.1811674.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseHealthcare resource burdenNovel trial designsClinical trial researchSignificant healthcareCase definitionClinical trialsEfficacious treatmentNew therapiesEndpoint definitionsTrial designTreatment targetsMetabolic diseasesTrial researchClinical researchDrug development processQuality data reportingDrug approvalDiseaseResource burdenRegulatory pathwaysDrug development
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplications